JP2020529473A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020529473A5 JP2020529473A5 JP2020528498A JP2020528498A JP2020529473A5 JP 2020529473 A5 JP2020529473 A5 JP 2020529473A5 JP 2020528498 A JP2020528498 A JP 2020528498A JP 2020528498 A JP2020528498 A JP 2020528498A JP 2020529473 A5 JP2020529473 A5 JP 2020529473A5
- Authority
- JP
- Japan
- Prior art keywords
- sample
- antibody
- monoclonal antibody
- disease
- synuclein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000003802 alpha-Synuclein Human genes 0.000 claims description 15
- 108090000185 alpha-Synuclein Proteins 0.000 claims description 15
- 230000027455 binding Effects 0.000 claims description 14
- 208000034799 Tauopathies Diseases 0.000 claims description 13
- 238000009739 binding Methods 0.000 claims description 13
- 206010012289 Dementia Diseases 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 208000024827 Alzheimer disease Diseases 0.000 claims description 9
- 210000002682 neurofibrillary tangle Anatomy 0.000 claims description 7
- 239000000427 antigen Substances 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 239000000178 monomer Substances 0.000 claims description 5
- 206010003694 Atrophy Diseases 0.000 claims description 4
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 4
- 230000037444 atrophy Effects 0.000 claims description 4
- 230000002490 cerebral effect Effects 0.000 claims description 4
- 230000001054 cortical effect Effects 0.000 claims description 4
- 230000007850 degeneration Effects 0.000 claims description 4
- 208000025688 early-onset autosomal dominant Alzheimer disease Diseases 0.000 claims description 4
- 208000015756 familial Alzheimer disease Diseases 0.000 claims description 4
- 210000004498 neuroglial cell Anatomy 0.000 claims description 4
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 4
- 208000009829 Lewy Body Disease Diseases 0.000 claims description 3
- 201000002832 Lewy body dementia Diseases 0.000 claims description 3
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 230000028993 immune response Effects 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 210000004558 lewy body Anatomy 0.000 claims description 3
- 229910052709 silver Inorganic materials 0.000 claims description 3
- 239000004332 silver Substances 0.000 claims description 3
- 210000003582 temporal bone Anatomy 0.000 claims description 3
- 229960005486 vaccine Drugs 0.000 claims description 3
- 238000001962 electrophoresis Methods 0.000 claims description 2
- 238000001262 western blot Methods 0.000 claims description 2
- 239000000835 fiber Substances 0.000 claims 8
- 229940079593 drug Drugs 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 230000015572 biosynthetic process Effects 0.000 claims 4
- 230000002776 aggregation Effects 0.000 claims 3
- 238000004220 aggregation Methods 0.000 claims 3
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 claims 2
- 101710184277 Insulin-like growth factor 1 receptor Proteins 0.000 claims 2
- 102000007238 Transferrin Receptors Human genes 0.000 claims 2
- 108010033576 Transferrin Receptors Proteins 0.000 claims 2
- 210000004408 hybridoma Anatomy 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 230000008499 blood brain barrier function Effects 0.000 claims 1
- 210000001218 blood-brain barrier Anatomy 0.000 claims 1
- 230000008859 change Effects 0.000 claims 1
- 230000019771 cognition Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000009467 reduction Effects 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762540435P | 2017-08-02 | 2017-08-02 | |
| US62/540,435 | 2017-08-02 | ||
| PCT/CA2018/050952 WO2019023809A1 (en) | 2017-08-02 | 2018-08-02 | ANTIBODIES BINDING TO ACTIVE ALPHA-SYNUCLEINE |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020529473A JP2020529473A (ja) | 2020-10-08 |
| JP2020529473A5 true JP2020529473A5 (https=) | 2021-08-12 |
| JP7204235B2 JP7204235B2 (ja) | 2023-01-16 |
Family
ID=65232133
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020528498A Active JP7204235B2 (ja) | 2017-08-02 | 2018-08-02 | 活性型α－シヌクレインに結合する抗体 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11098108B2 (https=) |
| EP (1) | EP3661961A4 (https=) |
| JP (1) | JP7204235B2 (https=) |
| KR (1) | KR102826089B1 (https=) |
| CN (1) | CN111225923B (https=) |
| AU (1) | AU2018312441B2 (https=) |
| BR (1) | BR112020001970A2 (https=) |
| IL (1) | IL272361B2 (https=) |
| SA (1) | SA520411188B1 (https=) |
| WO (1) | WO2019023809A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10364286B2 (en) * | 2016-12-22 | 2019-07-30 | H. Lundbeck A/S | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation |
| BR112019013953A2 (pt) | 2017-01-06 | 2020-02-11 | Abl Bio Inc. | Anticorpo anti-a-syn e uso do mesmo |
| CA3051839A1 (en) | 2017-02-17 | 2018-08-23 | Bristol-Myers Squibb Company | Antibodies to alpha-synuclein and uses thereof |
| EP3618870A4 (en) | 2017-05-01 | 2021-04-21 | The Trustees of The University of Pennsylvania | MONOCLONAL ANTIBODIES AGAINST ALPHA-SYNUCLEIN FIBRILLES |
| EP3661961A4 (en) | 2017-08-02 | 2021-04-14 | Stressmarq Biosciences Inc. | ANTIBODIES BINDING TO ACTIVE ALPHA-SYNUCLEIN |
| EP3725806A4 (en) | 2017-12-14 | 2022-03-30 | ABL Bio Inc. | BISPECIFIC ANTIBODIES AGAINST A-SYN/IGF1R AND ASSOCIATED USE |
| EP4268842A3 (en) * | 2019-06-14 | 2024-05-22 | ABL Bio, Inc. | BISPECIFIC ANTIBODY AGAINST a-SYN/IGF1R AND USE THEREOF |
| US20230025707A1 (en) * | 2019-11-19 | 2023-01-26 | The Trustees Of The University Of Pennsylvania | Anti-Alpha-Synuclein Monoclonal Antibodies, and Methods Using Same |
| NL2025332B1 (en) | 2020-04-10 | 2021-10-26 | Syngle Therapeutics B V | Novel alpha-synuclein binding antibodies, or antigen binding portions thereof. |
| KR102505164B1 (ko) * | 2020-09-29 | 2023-02-28 | 서울대학교산학협력단 | 신경퇴행성 질환의 예방 또는 치료용 펩타이드 및 이를 포함하는 약학 조성물 |
| CN113912713B (zh) * | 2021-12-15 | 2022-03-08 | 北京凯祥弘康生物科技有限公司 | 一种抗α-突触核蛋白的单克隆抗体及其应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3823313A1 (de) | 1988-07-09 | 1990-01-11 | Henkel Kgaa | Fussbodenreinigungsgeraet |
| US20040143093A1 (en) | 2002-07-11 | 2004-07-22 | Ralph Zahn | Method for inducing a conformational transition in proteins, such as pathogenic/infectious proteins, and their use |
| US9034337B2 (en) * | 2003-10-31 | 2015-05-19 | Prothena Biosciences Limited | Treatment and delay of outset of synucleinopathic and amyloidogenic disease |
| GB0624500D0 (en) * | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
| PT2282758T (pt) | 2008-04-29 | 2019-02-12 | Bioarctic Ab | Anticorpos e vacinas para uso em métodos terapêuticos e diagnósticos para perturbações relacionadas com a alfa-sinucleína |
| WO2009152607A1 (en) * | 2008-06-16 | 2009-12-23 | Ottawa Hospital Research Institute | Methods and kits for diagnosing neurodegenerative disease |
| CN102317316B (zh) | 2008-12-19 | 2014-08-13 | 帕尼玛制药股份公司 | 人抗α突触核蛋白自身抗体 |
| JP5894939B2 (ja) * | 2010-02-26 | 2016-03-30 | バイオアークティック ニューロサイエンス アーベー | プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用 |
| CA2818173C (en) | 2010-11-30 | 2022-05-03 | Genentech, Inc. | Low affinity blood brain barrier receptor antibodies and uses therefor |
| CA2840224C (en) | 2011-06-22 | 2019-08-13 | The General Hospital Corporation | Treatment of proteinopathies |
| SI2723379T1 (sl) | 2011-06-23 | 2019-03-29 | Biogen International Neuroscience Gmbh | Molekule, ki se vežejo ma anti alfa-sinuklein |
| DK2807188T3 (da) * | 2012-01-27 | 2019-10-07 | Prothena Biosciences Ltd | Humaniserede antistoffer, der genkender alpha-synuclein |
| EP3594240B1 (en) | 2013-05-20 | 2023-12-06 | F. Hoffmann-La Roche AG | Anti-transferrin receptor antibodies and methods of use |
| LT3071597T (lt) * | 2013-11-21 | 2020-10-12 | F. Hoffmann-La Roche Ag | Antikūnai prieš alfa-sunukleiną ir jų naudojimo būdai |
| DK3114141T3 (da) | 2014-03-06 | 2020-08-10 | Nat Res Council Canada | Insulinlignende vækstfaktor 1-receptor-specifikke antistoffer og anvendelse deraf |
| PE20170088A1 (es) | 2014-03-06 | 2017-03-09 | Nat Res Council Canada | Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos |
| NZ724869A (en) | 2014-03-06 | 2022-07-01 | Nat Res Council Canada | Insulin-like growth factor 1 receptor -specific antibodies and uses thereof |
| CN103983778B (zh) * | 2014-05-08 | 2016-04-13 | 首都医科大学宣武医院 | 一种检测受实验者体液体外促进疾病相关蛋白聚合能力的方法 |
| CA2874083C (en) * | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
| AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
| EP3661961A4 (en) | 2017-08-02 | 2021-04-14 | Stressmarq Biosciences Inc. | ANTIBODIES BINDING TO ACTIVE ALPHA-SYNUCLEIN |
-
2018
- 2018-08-02 EP EP18840781.1A patent/EP3661961A4/en active Pending
- 2018-08-02 JP JP2020528498A patent/JP7204235B2/ja active Active
- 2018-08-02 BR BR112020001970-4A patent/BR112020001970A2/pt unknown
- 2018-08-02 CN CN201880051765.4A patent/CN111225923B/zh active Active
- 2018-08-02 AU AU2018312441A patent/AU2018312441B2/en active Active
- 2018-08-02 KR KR1020207003980A patent/KR102826089B1/ko active Active
- 2018-08-02 US US16/635,943 patent/US11098108B2/en active Active
- 2018-08-02 WO PCT/CA2018/050952 patent/WO2019023809A1/en not_active Ceased
- 2018-08-02 IL IL272361A patent/IL272361B2/en unknown
-
2020
- 2020-01-29 SA SA520411188A patent/SA520411188B1/ar unknown
-
2021
- 2021-07-21 US US17/381,661 patent/US11919947B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020529473A5 (https=) | ||
| JP7227312B2 (ja) | 抗Ｎ３ｐＧｌｕアミロイドベータペプチド抗体およびその使用 | |
| TWI634126B (zh) | 抗－N3pGlu 類澱粉β肽抗體及其用途 | |
| US9895429B2 (en) | Antibodies that bind amyloid oligomers | |
| KR101999872B1 (ko) | 혈뇌 장벽 투과성의 조정에 있어서의 세마포린-4d 결합 분자의 용도 | |
| US11098108B2 (en) | Antibody binding active alpha-synuclein | |
| CA3111569A1 (en) | Anti-trem-2 agonist antibodies | |
| AU2022252753A1 (en) | ANTIBODIES TO a-SYNUCLEIN AND USES THEREOF | |
| TWI873576B (zh) | ＲＧＭａ結合蛋白質及其使用 | |
| JP2022122865A5 (https=) | ||
| US12116407B2 (en) | Methods of treating neurodegenerative diseases | |
| US20230279098A1 (en) | Compounds and methods targeting interleukin-34 | |
| JP2023537761A5 (https=) | ||
| CN114423450A (zh) | 用于疗法中的抗分拣蛋白抗体 | |
| JP2025507569A5 (https=) | ||
| JP2022528953A (ja) | 抗タウｃ３抗体及びその使用 | |
| WO2026035942A1 (en) | Combinatorial therapy for alzheimer's disease | |
| WO2025119350A1 (zh) | 靶向Tau的特异性结合蛋白及其应用 | |
| TW202434285A (zh) | 與異常蛋白質之聚集體形成相關之疾病的預防或治療劑 | |
| JP2026504818A (ja) | 抗アミロイドβプロトフィブリル／オリゴマー抗体およびその使用 | |
| HK40022840A (en) | ANTIBODIES TO α‐SYNUCLEIN AND USES THEREOF | |
| KR20240063995A (ko) | 신경퇴행성 장애를 치료하기 위한 항-세마포린-4d 결합 분자의 사용을 위한 예측 결과 프로파일링 |